Amifampridine clinical trials
Also written Firdapse.
How each study uses Amifampridine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Amifampridine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Nov 2018 · FIRDAPSE · NDA 208078 (FDA, Drugs@FDA)
- European Union
- 23 Dec 2009 · Firdapse (previously Zenas) · EMEA/H/C/001032 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 8
Catalyst Pharmaceuticals, Inc. (7) · Assistance Publique - Hôpitaux de Paris (2) · Augusta University (1) · Centre Hospitalier Universitaire, Amiens (1) · Wake Forest University Health Sciences (1) · Jacobus Pharmaceutical (1) · FDA Office of Orphan Products Development (1) · University of Aarhus (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Potassium channel blockers source
Studies
Open first, then newest update. How each study uses Amifampridine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Pyridostigmine and Amifampridine for Myasthenia GravisRecruitingPhase 3Leiden University Medical CenterNCT05919407Written as Amifampridine (base) with modified releaseHow we know
- Firdapse for Post-BOTOX Vocal WeaknessCompletedPhase 2Augusta UniversityNCT05123053Written as AmifampridineHow we know
- Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of BotulismCompletedPhase 2/3Centre Hospitalier Universitaire, AmiensNCT01441557Written as 3,4-diaminopyridineHow we know
- Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinACompletedPhase 1Wake Forest University Health SciencesNCT05769478Written as AmifampridineHow we know
- Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)TerminatedPhase 3Catalyst Pharmaceuticals, Inc.NCT03579966Written as Amifampridine PhosphateHow we know
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGCompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT03304054Written as Amifampridine PhosphateHow we know
- Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3TerminatedPhase 2Catalyst Pharmaceuticals, Inc.NCT03819660Written as Amifampridine Phosphate 10 MG Oral TabletHow we know
- Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 PatientsCompletedPhase 2Catalyst Pharmaceuticals, Inc.NCT03781479Written as Amifampridine PhosphateHow we know
- Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesCompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT02562066Written as amifampridine phosphateHow we know
- DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada SyndromeTerminatedPhase 3Assistance Publique - Hôpitaux de ParisNCT00701077Written as 3,4-Di-amino-PyridineHow we know
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)CompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT02970162Written as Amifampridine PhosphateHow we know
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT01377922Written as Amifampridine PhosphateHow we know
- Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeCompletedPhase 2Jacobus PharmaceuticalNCT01511978Written as Continuous 3,4-DAPHow we know
- Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic SyndromeCompletedNot applicableFDA Office of Orphan Products DevelopmentNCT00004832Written as 3,4-diaminopyridineHow we know
- Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT00190268Written as 3,4-diaminopyridineHow we know
- Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic StimulationCompletedPhase 2University of AarhusNCT00342381Written as 3,4-diaminopyridineHow we know
Codes
What other systems call Amifampridine · ClinicalTrials.gg INT006805
- MeSH (NLM) D000077770AmifampridineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RU4S6E2G0JAMIFAMPRIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 2106338Confirmed FDA, Wikidata
- Wikidata Q411707amifampridineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82687AmifampridineOne source FDA
- DrugBank DB11640One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077770 | Amifampridine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RU4S6E2G0J | AMIFAMPRIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2106338 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411707 | amifampridine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82687 | Amifampridine | One source FDA |
| DrugBank | DB11640 | — | One source Wikidata |
Also registered as amifampridine phosphate (UNII 8HF8FIN815 · RxNorm 2106337).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.